Anzeige
Mehr »
Login
Sonntag, 06.04.2025 Börsentäglich über 12.000 News von 688 internationalen Medien
Nach sensationellem Forschungsdurchbruch! Welche Aktie am Montag outperformen könnte...
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3ES01 | ISIN: US15713L1098 | Ticker-Symbol: DP8
Tradegate
04.04.25
09:16 Uhr
10,900 Euro
+0,800
+7,92 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CERVOMED INC Chart 1 Jahr
5-Tage-Chart
CERVOMED INC 5-Tage-Chart
RealtimeGeldBriefZeit
9,90010,30004.04.

Aktuelle News zur CERVOMED Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiCervoMed Inc.: Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD 20252
18.03.CervoMed Inc. - 8-K, Current Report5
18.03.CervoMed Inc. (CRVO): The Best Short-Term Stock to Buy Right Now6
17.03.CervoMed Inc. - S-8, Securities to be offered to employees in employee benefit plans2
17.03.CervoMed Inc. Full Year Loss Rises13
CERVOMED Aktie jetzt für 0€ handeln
17.03.CervoMed Inc. - 10-K, Annual Report3
17.03.CervoMed GAAP EPS of -$2.02 misses by $0.17, revenue of $9.73M beats by $0.39M2
13.03.CervoMed's Dementia Study's 16-Week Data 'Compelling Enough To Move From Sidelines' Analyst Says4
13.03.Jones Trading lifts CervoMed stock rating, sets $15 target13
12.03.Chardan lifts CervoMed stock rating to Buy, targets $145
12.03.CervoMed Inc. Stock Soars 152%7
11.03.Brookline raises CervoMed stock rating to buy, sets $16 target40
10.03.CervoMed Inc. - 8-K, Current Report2
10.03.CervoMed Inc.: CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies101A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p Improvement (p=0.035 against either old capsules or placebo) also demonstrated on the...
► Artikel lesen
19.02.Why CervoMed (CRVO) Is Advancing Today1
18.02.XFRA NEW INSTRUMENTS AVAILABLE ON XETRA 18.02.2025453The following instruments on XETRA do have their first trading 18.02.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 18.02.2025 Aktien 1 GB00BN0VZ646 Ferrari Group PLC 2...
► Artikel lesen
31.01.CervoMed meldet Fortschritte bei Demenz-Medikamententest10
31.01.CervoMed reports progress in dementia drug trial3
31.01.CervoMed Inc. - 8-K, Current Report-
12.12.24CervoMed Inc.: CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)180BOSTON, Dec. 12, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) (the "Company"), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced...
► Artikel lesen
Seite:  Weiter >>
40 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1